Arbutus Biopharma Corp  

(Public, NASDAQ:ABUS)   Watch this stock  
Find more results for NASDAQ:TKMR
4.10
-0.11 (-2.61%)
Jul 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.05 - 4.20
52 week 2.72 - 11.50
Open 4.18
Vol / Avg. 87,635.00/187,883.00
Mkt cap 224.50M
P/E     -
Div/yield     -
EPS -1.26
Shares 54.63M
Beta 1.24
Inst. own 32%
Aug 3, 2016
Q2 2016 Arbutus Biopharma Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 8, 2016
Tekmira Pharmaceuticals Corp Annual Shareholders Meeting (Estimated)
Jun 22, 2016
Arbutus Biopharma Corp at JMP Securities Life Sciences Conference
Jun 9, 2016
Arbutus Biopharma Corp at Jefferies Healthcare Conference
May 19, 2016
Arbutus Biopharma Corp Annual Shareholders Meeting
May 10, 2016
Arbutus Biopharma Corp at Bank of America Merrill Lynch Health Care Conference
May 4, 2016
Q1 2016 Arbutus Biopharma Corp Earnings Call
May 4, 2016
Q1 2016 Arbutus Biopharma Corp Earnings Release
May 2, 2016
Arbutus Biopharma Corp at Bloom Burton & Co. Healthcare Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -2632.50% -245.73%
Operating margin -3312.93% -411.38%
EBITD margin - -213.36%
Return on average assets -9.00% -14.72%
Return on average equity -11.73% -19.23%
Employees 85 -
CDP Score - -

Address

100-8900 Glenlyon Pky
BURNABY, BC V5J 5J8
Canada
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Officers and directors

Vivek Ramaswamy Chairman of the Board
Age: 29
Bio & Compensation  - Reuters
Mark J. Murray Ph.D. President, Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Bruce G. Cousins Chief Financial Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Elizabeth Howard Executive Vice President, General Counsel
Age: 62
Bio & Compensation  - Reuters
Peter Lutwyche Ph.D. Chief Technology Officer
Age: 50
Bio & Compensation  - Reuters
Michael Joseph Sofia Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
William Thomas Symonds III Chief Development Officer, Director
Age: 47
Bio & Compensation  - Reuters
Michael J. Abrams Ph.D. Managing Director - Non-HBV Assets
Age: 59
Bio & Compensation  - Reuters
Patrick T. Higgins Chief Business Officer
Age: 58
Bio & Compensation  - Reuters
Mark Kowalski M.D. Ph.D. Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters